Phenomics Australia in partnership with Therapeutic Innovation Australia (TIA), Bioplatforms Australia (BPA), and the National Deuteration Facility (NDF), is thrilled to announce the successful recipients of the Pipeline Accelerator 2024-25 (Round 2).
Enabled by the National Collaborative Research Infrastructure Strategy (NCRIS), all four NCRIS providers mentioned above are working together to help address the medical products challenge outlined in the 2021 National Research Infrastructure (NRI) Roadmap. Together, they provide academic researchers and SMEs seamless access to world-class Australian translational research infrastructure, spanning the molecular basis of health and disease through to clinical trials.
This round, 40 projects, including one Technical Feasibility Assessment (TFA), will share a total of $1,324,362 in voucher awards with a total cash co-investment fund of $1,745,302. facilitating access to national research infrastructure (NRI) to accelerate therapeutic translation and improve human health. These vouchers will subsidise the cost to access these translation NRIs to accelerate therapeutic translation and improve human health including, but not limited to, diabetes, heart disease, pain relief, cancer therapy, neurological disorders and women’s health.
Nine recipients were awarded the Phenomics Australia Pipeline Accelerator 2024-25 (Round 2) and are listed below.
Among the recipients, we would like to highlight Prof. Claudia Nold (Hudson Institute of Medical Research) project on novel immunologic intervention for interferon-driven autoimmune diseases. This project is jointly supported by the Monash Organoid Program (Monash Uni) a Phenomics Australia node and the Monash Proteomics and Metabolomics Platform (Monash Uni) a Bioplatforms Australia node. We would also like to highlight Dr Tan Nguyen (Walter Eliza Hall Institute/ exteRNA). This Small and Medium-sized Enterprise (SME) project, Target identification of novel anti-cancer therapeutic, is jointly supported by the Monash Functional Genomics Platform (Monash Uni), a Phenomics Australia node and the Drug Target Identification Platform, a Bioplatforms Australia node.
Notably, several recipients are continuing their journey with us – a testament to its impact and value in advancing therapeutic research. For instance, A/Prof. Amee George from the Australian National University has previously received support from TIA and, in this round, is receiving support from Phenomics Australia, highlighting the sustained value of these initiatives.
Phenomics Australia’s Pipeline Accelerator awards:
Click here to see the TIA voucher recipients.
The 9 recipients of the Phenomics Australia Pipeline Accelerator 2024-25 (Round 2) are listed below:
Click on the image to see the Phenomics Australia node involved
A/Prof. Amee George (The Australian National University)
Phenomics Australia node: Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI)
Developing humanised models of Diamond Blackfan Anaemia Syndrome
Dr Ao Wen Zhuang (The University of Melbourne)
Phenomics Australia node: Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI)
Patient-derived iPSC airway epithelial assay systems to develop Jagged-1 inhibitors targeting the root cause of muco-obstructive lung diseases
Dr Christian Makhoul (The University of Melbourne)
Phenomics Australia node: Victorian Centre for Functional Genomics (PeterMac)
CRISPR phenotype screen and machine learning to understand Motor Neurone Disease pathogenesis
Prof. Claudia Nold (Hudson Institute of Medical Research)
Phenomics Australia node: Monash Organoid Program (Monash Uni)
Bioplatforms Australia node: Monash Proteomics and Metabolomics Platform (Monash Uni)
Novel Immunologic Intervention for Interferon Driven Autoimmune Diseases
Dr Harriet Fitzgerald (Hudson Institute of Medical Research)
Phenomics Australia node: Monash Organoid Program (Monash Uni)
Determining the role of endometrial dysfunction in endometriosis
Prof. Leanne Dibbens (University of South Australia)
Phenomics Australia nodes: Australian Transgenic Drosophila Facility (PeterMac)
Identifying re-purposed drugs for KCNT1 epilepsy using cell and animal models
Ms Lucy Bradbury (University of Queensland)
Phenomics Australia node: Australian Organoid Facility (UQ)
Development of a Primary CNS Lymphoma (PCNSL)-Brain Organoid co-culture model
Dr Travis Ruan (Garvan Institute of Medical Research)
Phenomics Australia node: Victorian Centre for Functional Genomics (PeterMac)
Reprogramming the Breast Cancer Microenvironment to Improve Anti-Tumour Immunity
Dr Tan Nguyen (Walter and Eliza Hall Institute/exteRNA)
Phenomics Australia node: Monash Functional Genomics Platform (Monash)
Bioplatforms Australia node: Drug Target Idenfitication Platform (Monash)
Target identification of novel anti-cancer therapeutic
Contact us to know more about this voucher scheme that aims to support therapeutic development projects by providing up to $50,000 with at least 50% matching co-investment to be provided by the applicant.
Phenomics Australia, Bioplatforms Australia and TIA are three of the six members of NCRIS Health Group that works closely with each other and provide seamless access to world-class health and medical research infrastructure and expertise.
